Depending on the severity of dry eye disease symptoms and their underlying causes, there are treatments that can help produce more tears, soothe your eyes and ease your discomfort. Treatments can ...
Aldeyra Therapeutics has once again filed for Food and Drug Administration of its proposed reproxalap drug candidate for the treatment of signs and symptoms of dry-eye disease.
Aldeyra Therapeutics has resubmitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for topical ...
Tears evaporate and may cause dryness and irritation. Learn what evaporative dry eye is and what remedies to try for it.
finds a clinical trial from China published by The BMJ today The researchers suggest that laughter exercise could be an initial treatment for relieving symptoms of dry eye disease. Dry eye disease ...
Dry eye syndrome can be a complex disease with symptoms ranging from mild irritation ... laughter exercise could serve as a first-line, home-based treatment for people with symptomatic dry eye ...
Dry eye disease affects up to 15% of the U.S. population and is one of the largest markets in the ophthalmology field.
Common symptoms include uncomfortable ... and those who had recently used contact lenses or any dry eye disease treatment were excluded. The laughter exercise group watched an instructional ...
The researchers suggest that laughter exercise could be an initial treatment for relieving symptoms of dry eye disease. Dry eye disease (DED) is a chronic condition estimated to affect around 360 ...
CHENNAI: We’ve all heard people shouting “Ho, Ho, Ha, Ha, Ha” in parks, and when we follow the sounds, we often discover it’s ...
In addition to physical symptoms, a growing body of evidence ... Participants with severe corneal staining, history of dry eye treatments, contact lenses, eye surgery, trauma, eye infection ...
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today ...